Floatz logo

gs1191-0445

Severe Hemophilia A

Gritgen Therapeutics Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Severe Hemophilia A cohort.

Asset / SponsorPhaseRating
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
AryoGen Pharmed Co.
Phase 4BBB
Emicizumab
Chulalongkorn University
Phase 4BBB
Human-Cl Rhfviii
Octapharma
Phase 3BBB
Rfviiifc
Bioverativ Therapeutics Inc.
Phase 3BB
Frsw117
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3BB

View all 21 →

Same molecule, other indications

gs1191-0445 is also rated in:

hemophilia ADormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →